Esperion Therapeutics Inc

Drug Manufacturers-Specialty & Generic

Prices are adjusted according to historical splits.

Esperion Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$137.16 million
Book Value:
Revenue TTM:
$75.48 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Esperion Therapeutics Inc had its IPO on 2013-06-26 under the ticker symbol ESPR.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Esperion Therapeutics Inc has a staff strength of 199 employees.

Stock update

Shares of Esperion Therapeutics Inc opened at $1.54 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $1.52 - $1.74, and closed at $1.6.

This is a +2.56% increase from the previous day's closing price.

A total volume of 8,100,446 shares were traded at the close of the day’s session.

In the last one week, shares of Esperion Therapeutics Inc have slipped by -12.09%.

Esperion Therapeutics Inc's Key Ratios

Esperion Therapeutics Inc has a market cap of $137.16 million, indicating a price to book ratio of 98.4236 and a price to sales ratio of 5.982.

In the last 12-months Esperion Therapeutics Inc’s revenue was $75.48 million with a gross profit of $-70419000 and an EBITDA of $-179000992. The EBITDA ratio measures Esperion Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Esperion Therapeutics Inc’s operating margin was -237.83% while its return on assets stood at -35.64% with a return of equity of -260.79%.

In Q4, Esperion Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 22.2%.

Esperion Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-3.59 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -4.78. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Esperion Therapeutics Inc’s profitability.

Esperion Therapeutics Inc stock is trading at a EV to sales ratio of 6.935 and a EV to EBITDA ratio of -2.6749. Its price to sales ratio in the trailing 12-months stood at 5.982.

Esperion Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$247.94 million
Total Liabilities
$92.31 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Esperion Therapeutics Inc ended 2023 with $247.94 million in total assets and $0 in total liabilities. Its intangible assets were valued at $247.94 million while shareholder equity stood at $-323778000.00.

Esperion Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $92.31 million in other current liabilities, 75000.00 in common stock, $-1340036000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $124.78 million and cash and short-term investments were $166.86 million. The company’s total short-term debt was $384,000 while long-term debt stood at $259.90 million.

Esperion Therapeutics Inc’s total current assets stands at $246.68 million while long-term investments were $42.09 million and short-term investments were $42.09 million. Its net receivables were $33.73 million compared to accounts payable of $23.04 million and inventory worth $35.20 million.

In 2023, Esperion Therapeutics Inc's operating cash flow was $-11794000.00 while its capital expenditure stood at $0.

Comparatively, Esperion Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Esperion Therapeutics Inc stock is currently trading at $1.6 per share. It touched a 52-week high of $8.87 and a 52-week low of $8.87. Analysts tracking the stock have a 12-month average target price of $11.59.

Its 50-day moving average was $5.31 and 200-day moving average was $6.48 The short ratio stood at 9.4 indicating a short percent outstanding of 0%.

Around 81.6% of the company’s stock are held by insiders while 8572.4% are held by institutions.

Frequently Asked Questions About Esperion Therapeutics Inc

The stock symbol (also called stock or share ticker) of Esperion Therapeutics Inc is ESPR

The IPO of Esperion Therapeutics Inc took place on 2013-06-26

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Fanhua Inc (FANH)
Invesque Inc (MHIVF)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.


3891 Ranchero Drive, Ann Arbor, MI, United States, 48108